Research Article
Correlation of Serum Soluble Interleukin-7 Receptor and Anti-C1q Antibody in Patients with Systemic Lupus Erythematosus
Table 1
Demographics of patients with systemic lupus erythematosus (SLE) (
).
| | Demographics | LN SLE | Non-LN SLE | |
| | Patient number (%) | 58/134 (43.28) | 76/134 (56.72) | NA | | Age (mean ± SEM) (range, years) | 37.34 ± 1.55 (18–65) | 39.27 ± 1.59 (12–68) | 0.2359 | | Gender (male/female) (% female) | 6/52 (89.66) | 10/66 (86.84) | NA | | Disease duration (mean ± SD) (range, years) | 6.23 ± 0.56 (0.5–20) | 5.30 ± 0.79 (0.2–18) | 0.3768 | | SLEDAI score (range) | 14.05 ± 0.97 (0–36) | 6.62 ± 0.52 (0–18) | <0.0001 | | ACL Ab (+) number (%) | 42/58 (72.41) | 48/76 (63.18) | NA | | Anti-C1q (+) number (%) | 49/58 (84.48) | 31/76 (40.79) | NA | | Anti-C1q (AU/mL) | 78.63 ± 16.87 | 26.88 ± 9.236 | <0.0001 | | Anti-dsDNA (+) number (%) | 58/58 (100) | 76/76 (100) | NA | | Anti-dsDNA (IU/mL) | 67.63 ± 11.70 | 48.33 ± 7.721 | 0.1554 | | ANA (+) number (%) | 57/58 (98.28) | 73/76 (96.05) | NA | | ANA titer | 3038 ± 466.2 | 2499 ± 376.5 | 0.3553 | | Anti-Rib-P (+) number (%) | 12/58 (20.69) | 12/76 (15.79) | NA | | Anti-Smith (Sm) (+) number (%) | 18/58 (31.03) | 15/76 (19.74) | NA | | Anti-SSA Ab (+) number (%) | 28/58 (48.28) | 27/76 (35.53) | NA | | Anti-SSB Ab (+) number (%) | 15/58 (25.86) | 10/76 (13.16) | NA | | pANCA (+) number (%) | 16/58 (27.59) | 17/76 (30.36) | NA | | cANCA (+) number (%) | 1/58 (1.72) | 0/76 (0.00) | NA | | C3 (µg/mL) | 0.5091 ± 0.0340 | 0.6680 ± 0.03485 | 0.0018 | | C4 (µg/mL) | 0.08557 ± 0.0082 | 0.1145 ± 0.0112 | 0.0508 |
|
|
Ab: antibody; ACL: anticardiolipin; ANA: antinuclear antibody; cANCA: cytoplasmic antineutrophil cytoplasmic antibody; LN: lupus nephritis; pANCA: perinuclear antineutrophil cytoplasmic antibody; Rib-P: ribosomal P-proteins; RNP: ribonucleoprotein; SSA: Sjogren’s syndrome A; SSB: anti-Sjogren’s syndrome B.
; and .
|
